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Treatment of hematological malignant disorders has been improved over the last years,
but high relapse rate mainly attributable to the presence of minimal residual disease
still persists. Therefore, it is of great interest to explore novel therapeutic strategies
to obtain long-term remission. Immune effector cells, and especially natural killer (NK)
cells, play a crucial role in the control of hematological malignancies. In this regard, the
efficiency of allogeneic stem cell transplantation clearly depends on the immune-mediated
graft versus leukemia effect without the risk of inducing graft versus host disease.
Alloreactive donor NK cells generated following hematopoietic stem cell transplantation
ameliorate the outcome of leukemia patients; in addition, in vivo transfer of in vitro
expanded NK cells represents a crucial tool for leukemia treatment. To improve NK cell
effector functions against resistant leukemia cells, novel immunotherapeutic strategies are
oriented to the identification, isolation, expansion, and administration of particular NK cell
subsets endowed with multifunctional anti-tumor potential and tropism toward tumor
sites. Moreover, the relationship between the emergence and persistence of distinct
NK cell subsets during post-graft reconstitution and the maintenance of a remission state
is still rather unclear.
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INTRODUCTION
Natural killer (NK) cells belong to innate lymphocytes that play an important role in the early
phase of immune defense against microbial infections, and tumor growth and dissemination.
They represent a population of highly specialized large granular lymphocytes capable of mediating
cytotoxic activity and endowed with the ability to release cytokines and chemokines when properly
activated by target cells or pro-inflammatory stimuli (1–3). During microbial infection or tumor
growth and invasion, NK cells can be rapidly recruited to and accumulate in the parenchyma of
injured organs, contributing to the elimination of infected or transformed cells as well as to the
recruitment and activation of other immune cells (4, 5). Thus, NK cells are important effectors in
the early phase of innate immune responses and play a crucial role as immune regulators of adaptive
immunity (6).
Activation of NK cell functional program results from a delicate balance of signals initiated by
a complex receptor system formed by both inhibitory and activating receptors. These receptors
are acquired during differentiation, and are oligoclonally distributed on mature NK cells; in most
instances, the inhibitory signals override the triggering ones (2).
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The inhibitory receptors that mainly bind to MHC class
I molecules are grouped into two classes: the killer cell
immunoglobulin-like receptor (KIR) family that includes recep-
tors for human leukocyte antigen (HLA)-A, -B, and -C group of
alleles, and theC-type lectin receptors, such as CD94/NKG2A that
binds to the non-classical HLA class I molecule, HLA-E.
Both the inhibitory receptor families have also an activating
counterpart with similar specificity but different ligand affinity,
showing inhibitory receptors greater ligand affinity with respect to
their activating counterpart. TheMHC I activating receptors pos-
sess a short intracellular domain and associate with a transducing
chain that initiates the activating signaling pathway when engaged
by ligands (7–9). The human KIR family consists of 13 genes and
2 pseudogenes, and displays a high degree of diversity that arises
from both variability in KIR content and allelic polymorphisms.
KIR genes are variably inherited by individuals and expressed by
NK cells in an oligoclonal manner.
Among non-MHC I NK cell activating receptors, the best
studied is the low-affinity Fc-γ receptor IIIA (CD16) involved
in the NK cell-mediated antibody-dependent cellular cytotoxicity
(ADCC) (10). Another important activating receptor is NKG2D
that binds to self-molecules undergoing up-regulation on stressed,
infected, or damaged cells belonging to MIC and ULBP fami-
lies (11). In addition, NK cell activating receptors also include
NKp44, NKp46, and NKp30 Ig-like molecules, collectively termed
natural cytotoxicity receptors (NCR), and DNAM-1 (CD226) that
cooperatively triggers natural killing (12–14).
Activating and inhibitory receptors are acquired during NK
cell differentiation and activation, and are selectively expressed on
distinct NK cell subsets. Recognition of MHC I receptors during
NK cell development is critical for the acquisition of the functional
competence through a process defined as NK cell education or
licensing (15, 16). Thus, based on the receptor repertoire and
expression levels, phenotypically distinct mature NK cell popula-
tions have been identified and suggested to represent specialized
subsets mediating different functions and endowed with distinct
migratory properties (17).
Natural killer cell differentiation primarily occurs in the bone
marrow (BM), although NK cell progenitors can undergo final
maturation also in the periphery, and the existence of a thymic
pathway of NK cell differentiation has been also described in
mice (18–20).
Fully mature, NK cells mainly circulate in the peripheral blood
(PB) but they can be also found in several lymphoid and non-
lymphoid organs, such as spleen, tonsils, lymph nodes, liver, intes-
tine, lungs, and uterus (1, 21–24). PB NK cells represent about
5–20% of total lymphocytes.
Two major human NK cell subsets, namely, CD56highCD16+/ 
and CD56lowCD16high, can be distinguished in the PB based
on the expression levels of the low-affinity Fc-receptor γ IIIA
(CD16) and the neural cell adhesion molecule (NCAM, CD56).
CD56highCD16+/  NK cells primarily secrete immunoregulatory
cytokines, whereas the CD56lowCD16high NK cell subset is the
major killer population mediating both natural cytotoxic activity
and ADCC. It is still matter of debate whether these subsets
are functionally distinct terminally differentiated NK cells or NK
cells at a different stage of maturation (17, 25). A sequential
relation between these twomajorNKcell subsets has been recently
reported in that it has been shown that CD56high NK cells have
longer telomeres than CD56low NK cells and can differentiate into
CD56low in humanized mice in the presence of human IL-15, thus
suggesting that they represent a more immature stage (26–28).
Recently, authors identified a distinct CD56low NK cell subset
based onCD16 expression levels in the BM and PB of healthy chil-
dren and acute lymphoblastic leukemia (ALL) pediatric patients
(Figure 1). The CD56lowCD16low NK cells are more prominent
in the BM, and in this organ their frequency further increases
in ALL children. Both BM and PB CD56lowCD16low NK cells
release IFNγ upon IL-12 plus IL-15 stimulation, and are the major
killer population against K562 erythroleukemia cells. However,
unlike healthy donors, BMandPBCD56lowCD16lowNKcells from
ALL children poorly degranulate in response to K562 target cell
stimulation. Interestingly, using PBNK cell subsets from two hap-
loidentical HSC donors as source of effector cells and the leukemic
blasts of the corresponding recipients as targets, CD56lowCD16low
NK cells are the unique population capable of killing leukemic
blasts (29).
Overall, our findings suggest that CD56lowCD16low NK
cells represent an intermediate state between CD56high and
CD56lowCD16high NK cells. However, the lower levels of CD16
may also imply that CD56lowCD16low NK cells represent a
post-activation stage, as a disintegrin and metalloproteinase-17
(ADAM-17)-dependent CD16 shedding can occur following NK
cell activation (30, 31). In this regard, in accordance with the
increased number of CD56lowCD16low NK cells in leukemic chil-
dren, our preliminary data indicate that ADAM-17 is signifi-
cantly more abundant in their BM plasma as compared to healthy
donors (32).
NK CELLS FOR HEMATOLOGICAL
CANCER THERAPY: ALLOREACTIVE
NK CELLS
The ability of NK cells to kill leukemic cells in mice without
T-cell involvement and prior sensitization was first reported in
1975 (33, 34). Thereafter, growing evidence showed that NK
cells preferentially lyse target cells expressing lower or aberrant
MHC class I molecules. Based on this evidence, Kärre et al.
formulated the missing self hypothesis, arguing that NK cells
survey the body for the expression of self-MHC class I molecules
and destroy cells on which they are missing (35). Only at the
beginning of the 1990s, MHC I inhibitory receptors were dis-
covered in the mouse and humans, and they were shown to
deliver negative signals to the NK cells, thus, preventing their
cytotoxic activity (2). Accordingly, the use of human NK cell
clones revealed that NK cells are unable to lyse autologous nor-
mal cells when they express inhibitory receptors for at least one
self class I allele. Subsequent findings indicated that NK cells
are endowed with alloreactivity and can lyse target cells lacking
MHC I molecules (36). This notion has had important clinical
implications.
The NK cell therapeutic potential was clearly demonstrated
when a potent anti-leukemic effect was observed in patients
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FIGURE 1 | CD56lowCD16low NK cells are a functionally and phenotypically distinct NK cell subset.
with acute myeloid leukemia (AML) undergoing mismatched/
haploidentical hematopoietic stem cell transplantation (HSCT).
This protocol of transplantation relied on the generation of allore-
active NK cells with a KIR repertoire unable to bind to host
MHC class I molecules, and was associated with a 65% prob-
ability of disease-free survival, decreased incidence of relapse,
and no increased incidence of graft versus host disease (GVHD)
in T-cell-depleted transplants (37). However, patients with KIR-
ligand incompatibility can be still at high risk of GVHD as T-
cell alloreactivity may dominate NK cell alloreactivity in min-
imally T-cell-depleted grafts and in T-cell-repleted transplants
(38). The AML-specific effect in unrelated donor transplantation
was observed only under particular conditions, including infusion
of high doses of stem cells, almost complete depletion of T-cells,
no post-grafting immunosuppression, and donors selected for the
perfect mismatch at HLA loci (39).
The KIR genes are polymorphic and are organized into
two broad haplotypes: group A KIR haplotype, which encodes
mainly inhibitory receptors (KIR2DL2/3, KIR3DL2/3, KIR2DL4,
KIR3DL1) and one activating receptor (KIR2DS4), and group
B KIR haplotype, which encodes both inhibitory (KIR2DL2/3,
KIR3DL2/3, KIR2DL5B/A, KIR2DL4, KIR3DL1) and several acti-
vating KIR (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5, KIR3DS1)
(Table 1) (40, 41).
Although the initial findings outlined the importance of
inhibitory KIRs on the outcome of HSCT, several later studies also
focused attention on the influence of activating KIRs. Thus, AML
patients transplanted with HSC from donor with alloreactive NK
cells carrying KIR2DS1 displayed a lower rate of leukemia relapse
as compared to those carrying KIR3DS1 who had no effect on
leukemic disease but showed a reduced risk of infection-related
mortality (42). Similarly, Mancusi et al. reported that transplan-
tation from donors with KIR2DS1 and/or KIR3DS1 resulted in
reduced non-relapse mortality and improved survival (43).
The KIR protective effects were dependent on high levels of
HLAC ligands and was restricted to donors with HLA-C1/C1 or
HLA C1/C2, whereas it was lost if the donors were HLA C2/C2.
This is probably due to the high levels of activating HLA C2
ligands that could induce NK cell tolerance, thus impairing their
anti-leukemic effector functions (42).
Variation of the KIR gene family and the impact of KIR-ligand
mismatch on the outcome of HSCT have been also addressed.
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TABLE 1 | Killer immunoglobulin-like (KIR) haplotypes.
HLA class I ligand Inhibitory Activating
A. Haplotype
3DL2 HLA-A(A*3, A*11) +
2DS4 HLA-C(C*5, C*16, A*11) +
3DL1 Bw4 +
3DS1 Bw4? +
2DL4 HLA-G +
3DP1  
2DL1 HLA-C(C2) +
2DP1  
2DL2 HLA-C(Cl/c2, few HLA-B) +
2DL3 HLA-C(Cl/c2, few HLA-B) +
3DL3 N.D +
B. Haplotype
3DL2 HLA-A(A*3, A*11) +
2DS4 HLA-C(C*5, C*16, A*11) +
2DS1 HLA-C(C2) +
2DS3/5 N.D +
2DL5A N.D +
3DL1 Bw4 +
3DS1 Bw4? +
2DL4 HLA-G +
3DP1  
2DL1 HLA-C(C2) +
2DP1  
2DS3/5 N.D +
2DL5B N.D +
2DL2 HLA-C(Cl/c2, few HLA-B) +
2DL3 HLA-C(Cl/c2, few HLA-B) +
2DS2 A11? +
3DL3 N.D +
Gray and white box contain telomeric and centrometric KIRs respectively; C1/c2 denotes
a strong reaction with C1 and weaker cross-reaction with C2; ? denotes uncertainty.
Kröger et al. analyzed the KIR haplotypes in leukemic patients
who received T-cell-depleted unrelated HSCT. They observed
that only patients that have received transplants from donors
carrying group A haplotype or a small number of activating KIR
genes, exhibit reduced relapse and increased disease-free survival.
This effect was observed only for AML/myelodysplastic syndrome
and to a lesser extent for chronic myeloid leukemia, whereas no
effect was evidentiated for ALL (44). The influence of donor and
recipient KIR genotype on the outcome of HSCT between HLA-
matched siblings was also reported byMcQueen et al. Transplants
were divided in four groups according to the combination ofA and
B KIR genotype in the donor and recipient. Better survival was
found to be associated with the donor lacking and the recipient
having group B KIR haplotype. When haplotype B was present
in the donor and absent in the recipient, increased relapse and
acute GVHD was observed only if recipient and donor were
homogyzous for HLAC1 KIR ligand and lacked HLAC2 ligand.
These findings could be attributable to the presence of activat-
ing KIRs in the graft, with a preferential promotion of GVHD
but not GVL response, as the activating KIRs on grafted NK or T
cells might cause host alloaggression and impaired reconstitution
of a responsive immune system (45). Conversely, a multicenter
analysis demonstrated a significant and substantial survival bene-
fit for AMLpatients receiving grafts fromunrelated donors having
1 or 2 KIR B haplotypes, thus providing evidence that donors with
KIR B haplotype should be used preferentially inHLA-matched or
HLA-mismatched unrelated donor transplantation (46). In addi-
tion, it is not the presence of the activating B haplotype by itself,
but rather the presence of three particular donor genes (2DL5A,
2DS1, and 3DS1) within the B haplotype that is associated with
reduced relapse (47). Moreover, AML patients transplanted with
HSC from donor with alloreactive NK cells carrying KIR2DS1
and/or KIR3DS1 also display a reduced mortality related to infec-
tions, and thus a better event-free survival (42, 43).
Although many reports demonstrate a therapeutic role for
alloreactive NK cells in AML, evidence are also available on
the importance of KIR-HLA matching. In this regard, Farag
et al. analyzed the outcome of 1571 unrelated donor–recipient
transplanted patients with myeloid malignancies by comparing
donor–recipient pairs, such as HLA-A, -B, -C, and -DRB1
matched, KIR-ligand-mismatched, and HLA-B and/or-C-
mismatched but KIR-ligand-matched, and reported that
treatment-related mortality, treatment failure, and overall
mortality were lowest only after matched transplantation (48).
No clear benefit has been observed for haploidentical HSCT
in adult ALL patients with respect to AML patients (37, 44).
However, successful results have been obtained in children with
ALL transplanted with haploidentical T cell depleted HSC (49).
A possible explanation for the distinct role of alloreactive NK
cells in pediatric versus adult ALL transplanted patients stems
from a recent report demostrating a differential activating ligand
repertoire on the leukemic cells. Pediatric ALL blasts exhibited
higher expression levels of both the DNAM-1 ligand Nec-2, and
the NKG2D ligands ULBP-1 and ULBP-3, as compared to adult
ALL blasts (50).
NK CELL RECONSTITUTION AFTER HSCT
AND ADOPTIVE INFUSION OF NK CELLS
After HSCT, the first class of lymphocytes which reconstitute
in the PB are NK cells that precede T cell reconstitution. The
earliest reconstituted NK cells exhibit a CD56high phenotype and
express high levels of NKG2A/CD94 and lower levels of inhibitory
KIR (51, 52). The analysis of the functional ability of NK cells
reconstituted after adult unrelated donor or umbilical cord blood
grafting reveal that NK cells fromT cell-depleted transplant recip-
ients without immunosuppression, display poor degranulating
ability, whereas degranulation is normal or increased in patients
undergoing T-cell-repleted transplants and receiving immuno-
suppression. Based on this observation, a role for T cells in NK cell
education and KIR acquisition has been suggested (53). However,
another study on the comparison of NK cell reconstitution in
T cell-repleted and T cell-depleted HLA-matched sibling, HSCT,
indicates that functional recovery of both uneducated and edu-
cated NK cells is similar in T cell-depleted and T cell-repleted
settings. Moreover, NKG2A+ donor NK cells are predominant
early after transplantation before expression of KIR, whereas the
NKG2A  NK cells expressing KIR for non-self ligand, remain tol-
erant in both settings, suggesting that NK cell subsets expressing
inhibitory receptors for non-self HLA class I molecules remain
hyporesponsive after HLA-matched HSCT (54).
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Overall, the analysis of the NK cell repertoire and functional
ability at different times after transplantation reveal a marked
hyporesponsiveness of NK cells early after transplantation (55).
Moreover, cytokine producing and degranulating abilities are
not co-expressed in reconstituting NK cells after allo-HSCT, as
target cell-induced IFNγ production is markedly diminished in all
transplant settings, whereas the cytotoxic activity is impaired only
in T cell-depleted HSCT. The decreased ability to produce IFNγ
is rapidly reverted by exposure to low dose of IL-15 suggesting a
potential therapeutic role for this cytokine by enhancing NK cell
protective ability against infection and relapse (56).
In accordance with these findings, our preliminary results on
the CD56lowCD16low NK cells indicate that like CD56high NK
cells this subset is present in the PB and BM already at 1month
post-T cell-depleted HSCT, and their number is increased with
respect to healthy individuals. However, unlike healthy donors,
no differences in CD56lowCD16low NK cell distribution between
the two tissue compartments during the first 6months afterHSCT
are observed. In transplanted patients, CD56lowCD16low NK cells
produce higher levels of IFNγ after IL-12 plus IL-15 stimulation,
but they are still the only NK cell degranulating subset when
challenged with K562 cells, although the extent of degranulation
is lower than that of healthy controls (Stabile et al. unpublished
observations).
Adoptive transfer of NK cells have been also considered a
promising therapeutic option in the treatment of hematologi-
cal malignancies, especially in T-cell-depleted haplo-SCT setting
because their potent GVL effect (55, 56).
The early clinical trials based on adoptive cell transfer, utilized
lymphokine-activated killer (LAK) cells generated from autolo-
gous PBMCs cultured in vitrowith high doses IL-2 for 3–7 days in
order to induce anti-tumor killer cells that mainly consisted of NK
cells (57–59). Systemic high doses of IL-2 were also administered
in order to activate the autologous NK cells in vivo; however,
in this case, severe toxicity occurred due to capillary leak syn-
drome induced by IL-2 (59, 60). Subcutaneous administration of
low doses of IL-2 alone or in combination with LAK cells gave
encouraging results only in patients with melanoma and renal
carcinoma (61, 62). Although these approaches augmented in vivo
activity of NK cells, no consistent efficacy of autologous NK-cell
therapy could be detected in patients with other cancer histotypes,
including hematological malignancies (62).
The failure of this kind of immunotherapy has been attributed
to downregulation of NK cell activity by KIR engagement by
self-MHC (37), competition with recipient’s lymphocytes for
cytokines and space, chronic immunosuppression induced by
tumor and/or expansion of Treg cells by IL-2 (63, 64). How-
ever, by analyzing cancer patients (metastatic melanoma, renal
cell carcinoma, refractory Hodgkin’s disease, and refractory
AML) subjected to adoptive transfer of human NK cells from
haploidentical-related donors, Miller and collaborators demon-
strated that transferred NK cells can be expanded in vivo and
that expansion is dependent on the more intense cyclophos-
phamide/fludarabine chemotherapy regimen that induces lym-
phopenia and high endogenous concentrations of IL-15, which
are not observed when lower doses of chemotherapy are admin-
istered. More importantly, 5 of 19 poor-prognosis AML patients
achieved complete remission after haploidentical NK cell therapy,
with a significant higher complete remission ratewhenKIR-ligand
mismatched donors were used (65). In accordance with the pres-
ence of high concentrations of IL-15 mature NK cells transferred
in high-risk AML patients undergoing haploHSCT, were found to
proliferate in vivo during the early days after haplo HSCT even in
the absence of exogenous IL-2 administration, and this resulted
in relative low patient relapse rate (66). Moreover, IL-15 together
with IL-12 and IL-18 was reported to increase the expression of
high affinity IL-2 receptor that was associated with increased NK
cell survival, proliferation, and effector function, thus leading to
propose immunotherapeutic strategies based on short cytokine
preactivation of NK cell before adoptive transfer and followed by
low doses of IL-2 therapy (67, 68).
The existence of NK cell subsets with distinct phenotype, func-
tional ability, and adhesion and chemotactic properties that drive
their tropism to different tissue compartments, strongly suggests
that NK cell-based therapies still require a better identification of
NK cell subsets endowed with optimal anti-tumor potential and
tropism to tumor sites, to achieve optimal clinical benefit.
CONCLUSION
Authors suppose that the identification and characterization of
multifunctionalNK cell subsets, which can be rapidlymobilized in
the PB andwith strong ability tomigrate to tumor sites, would pro-
vide new insights on the role played by NK cells under patholog-
ical conditions and, more importantly, would allow the design of
new approaches of adoptive immunotherapy to treat patients with
NK cell-susceptible hematological malignancies. Further studies
would also clarify the relationship between emergence and persis-
tence of distinct NK cell subsets during post-graft reconstitution
and the maintenance of a state of remission.
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